Result of Annual General Meeting 2022
Arix Bioscience PLC (ARIX)
Result of Annual General Meeting 2022
07-Jun-2022 / 16:44 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Result of Annual General Meeting 2022
LONDON, 7 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website.
No
RESOLUTION
VOTES FOR
%
VOTES AGAINST
%
TOTAL VOTES
% of ISC VOTED
VOTES WITHHELD
1
To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2021
63,669,622
99.99%
5,609
0.01%
63,675,231
49.29%
10,853
2
To approve the Directors' Remuneration Policy
63,589,770
99.90%
65,188
0.10%
63,654,958
49.28%
31,126
3
To approve the Directors' Remuneration Report
60,232,861
94.62%
3,422,747
5.38%
63,655,608
49.28%
30,476
4
To re-elect Peregrine Moncreiffe as a Director
60,068,424
94.35%
3,599,164
5.65%
63,667,588
49.29%
18,496
5
To re-elect Maureen O'Connell as a Director
59,600,160
93.61%
4,068,028
6.39%
63,668,188
49.29%
17,896
6
To re-elect Isaac Kohlberg as a Director
63,450,417
99.66%
217,771
0.34%
63,668,188
49.29%
17,896
7
To re-elect Robert Lyne as a Director
63,451,455
99.66%
216,733
0.34%
63,668,188
49.29%
17,896
8
To elect Sir Michael Bunbury as a Director
60,231,844
94.60%
3,436,344
5.40%
63,668,188
49.29%
17,896
9
To appoint BDO LLP as auditors of the Company
63,659,891
99.98%
12,947
0.02%
63,672,838
49.29%
13,246
10
To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration
63,667,766
99.99%
4,772
0.01%
63,672,538
49.29%
13,546
11
To authorise the Directors to allot shares
63,632,590
99.94%
40,130
0.06%
63,672,720
49.29%
13,364
12
Authority to disapply statutory pre‐ emption rights
58,648,467
92.11%
5,021,253
7.89%
63,669,720
49.29%
16,364
13
Additional authority to disapply statutory pre‐ emption rights
58,653,953
92.12%
5,015,767
7.88%
63,669,720
49.29%
16,364
14
To authorise the Company to purchase its own shares
63,648,630
99.96%
22,560
0.04%
63,671,190
49.29%
14,894
15
Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice
63,666,745
99.99%
8,786
0.01%
63,675,531
49.29%
10,553
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2022, which is available on Arix investor relations website.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
ISIN: GB00BD045071 Category Code: RAG TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 166768 EQS News ID: 1370371
End of Announcement EQS News Service